Deridre Kelly, Professor of Paediatric Hepatology at the University of Birmingham, sharen on X:
“New The Lancet Oncology – Phase2 Capmatinib in METex14 NSCLC
Objective response rate: 68%
Progression-free survival: 12.5 months
Overall survival: 21.4 months (1st-line), 16.8 months (later lines)
Adverse Events: edema 47%, nausea 35%, creatinine 21%, vomiting 20%
METex14 key biomarker for METi.”
Source: Deridre Kelly/X